(DAUNORUBICIN AND CYTARABINE) LIPOSOME (VYXEOS) Nursing Considerations

Join NURSING.com to watch the full lesson now.

Included In This Lesson

Outline

What is the Generic Name

(DAUNORUBICIN AND CYTARABINE) LIPOSOME

What is the Trade Name for (DAUNORUBICIN AND CYTARABINE) LIPOSOME

VYXEOS

What is the Indication for (DAUNORUBICIN AND CYTARABINE) LIPOSOME

  • 1 INDICATIONS AND USAGE VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older. VYXEOS is a liposomal combination of daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, a nucleoside metabolic inhibitor, that is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older. ( 1 )

 

 

View Our Nursing Pharmacology Course

 

References: https://open.fda.gov/

 

Other Pharm Resources
Join NURSING.com to watch the full lesson now.
[NextGen]
[NextGen]